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Abstract 
Extended Spectrum Beta Lactamases (ESBLs) are      first reported      in Klebsiella pneumonia in 
1983. These enzymes possess      the ability to inactivate susceptible β-lactam antibiotics i.e. 
penicillins, first, second and third generation cephalosporins and 
aztreonam, but not            cephamycins and carbapenems     
. Their mode of action is by      hydrolyzing the β-lactam ring. Even before the first β-lactam 
antibiotic (penicillin) was      developed, resistance to β-lactam antibiotics was observed     . 
ESBL      genes are plasmids- and transposons-     mediated, as such, can be spread easily to 
other species of bacteria. Resistance of ESBL-     producing bacteria to the β-lactam antibiotics 
is a continuing cause of public health problems     , it is increasingly being observed in 
community and nosocomial acquired infections. Detection and identification of these ESBLs in 
the laboratory is of prime importance for the selection of appropriate antibiotics to be used in 
the treatment of infections caused by ESBL-     producing bacteria. The aim of this review is to 
explain in detail     , several phenotypic methods used in the detection and confirmation of 
extended spectrum β lactamases. 
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Introduction 
Beta lactam antibiotics are a class of broad        
spectrum antibiotics that contain a β-lactam ring 
in their core molecular structures (Maria, 2013). 
They are among the most commonly prescribed 
antimicrobial agents worldwide to treat bacterial 
infections (Bradford, 2001; Shaikh et al., 2015). 
Prestinaci et. al., (2015), reported that their cost-
effectiveness, ease of use and tolerability make 
them the most widely used antibacterial 
agents. The effectiveness of these antibiotics has 
been decreased due to the development of 
resistant mechanisms in certain bacterial species 
(WHO, 2014) as a result of indiscriminate 
consumptions. Production of β-lactamases 
remains the major mechanism employed by      
bacteria to resist the effects of antimicrobial 
agents used against them (Ximin and Jun, 2013)
. The continuous      exposure of bacterial strains 
to multitude of β-lactam antibiotics has induced 
the dynamic and incessant production and 
mutation of β-
lactamases in these bacteria, thereby expanding 
their activity against the newly developed β-
lactam antibiotics (Shaikh et. al., 2015)     .      This      
class of enzymes that can break down these 
newer antibiotics are termed as Extended-
Spectrum Beta Lactamases (ESBLs) (Paterson 
and Bonomo, 2005; Pitout and Laupland, 2008; 
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Shaikh et. al., 2015). Extended Spectrum Beta 
Lactamases (ESBLs) are enzymes that mediate 
resistance to broad spectrum of β-lactam 
antibiotics such as penicillins, third generation 
cephalosporins (e.g. ceftazidime, cefotaxime, and 
ceftriaxone) and aztreonam, but not to 
cephamycins (cefoxitin and cefotetan) and 
carbapenems (Bonnet, 2004; Al-Muharrmi et. al., 
2008; Shaikhet. al., 2015) but are being inhibited 
by beta lactamase inhibitors like clavulanic acid 
(Al-Muharrmi et. al., 2008). 
The ability of bacteria to produce 
enzymes that destroy the Β-lactam antibiotics 
began even before penicillin was developed 
(Abrahan and Chain, 1940). The first β-lactamase 
was identified in an isolate of Escherichia coli in 
1940 (Abrahan and Chain, 1940; Turner, 2005; 
Gupta, 2007). Although β-lactamases are 
estimated to have existed for the past 2 billion 
years, their evolution and spread have been 
highly correlated to the anthropogenic 
development and prolificacy of β-lactam 
antibiotics during the past 60 years 
(Lachmayr et.al., 2009). Therefore, their 
detection is a major challenge for the clinical 
microbiologist because they may appear 
susceptible to certain Β-lactam antimicrobial 
agents during in vitro studies. This could result in 
treatment failure (Linscott and Brown, 2005) 
which may lead to high rates of morbidity and 
mortality in infectious diseases caused by the 
bacteria producing these enzymes (Kang et. al., 
2004). Therefore, the detection and  identificatio
n of ESBL-producing bacteria and the knowledge 
of their resistance are of paramount 
importance in selecting appropriate  antimicrobia
ls to be used in the treatment of infections      
caused by MDR bacteria, thereby reducing the 
spread of antibiotics resistant bacteria (ARB). 
AmpC β-lactamases belong to the Ambler class C 
and once expressed at high levels confer 
resistance to many Β-lactam antimicrobials, 
excluding the fourth generation cephalosporins 
and carbapenems (Deshpade et al., 2006). Unlike 
ESBLs, these enzymes are not inhibited by 
commercial β-lactamase inhibitors (clavunic acid, 
sulbactam or tazobactam), however, different 
types of inhibitors, such as boronic acid and 
cloxacillin have shown good inhibition (Pitout et. 
al., 2010).  
This review aims at explaining in detail     , 
several phenotypic methods used in the detection 
of extended spectrum β-lactamases. Numerous 
detection methods of ESBL have been proposed 
based on clinical microbiology techniques, these 
techniques include preliminary screening for ESBL 
production followed by confirmatory tests. The 
screening is usually done by disk diffusion 
techniques, while the phenotypic confirmatory 
methods rely mainly on the action of beta 
lactamase inhibitors such as clavulanic acid and 
tazobactam to increase the zone of inhibition. The 
various methods that will be reviewed in this 
study include Double Disc Synergy, Three 
dimensional, Vitek system, Disk 
combination, ESBL Chrom Agar, Broth Micro     
dilution, Nordmann/Dortet/Poirel (NDP) test, and 
E-test. 
ESBL Detection Methods 
Initial Screening Test for ESBL Production  
The Clinical and Laboratories Standard Institute 
(CLSI) as well as European Committee on 
Antimicrobial Susceptibility testing (EUCAST) 
recommended a two-step phenotypic approach in 
detecting ESBL production followed by 
confirmatory tests. The initial screening may be 
carried out by broth microdilution or disk diffusion 
method while the confirmatory test mainly relies 
on the action of beta lactamase inhibitors to 
enhance the zone of inhibition (EUCAST, 2012; 
Yarima et. al., 2019).  
Broth Microdilution 
This test has been recommended by both 
CLSI and EUCAST in screening of ESBL 
production. In this test, a concentration of 4µg/
mL of Cefpodoxime or 1 µg/mL of Ceftazidime, 
Aztreonam, Cefotaxime or Ceftriaxone are tested 
against the test bacteria. After incubation at 37oC 
for 16 hours. Growth at or above the screening 
concentrations preliminarily indicates possible 
ESBL production (i.e. for Escherichia coli, 
Klebsiella pneumoniae, and Klebsiella. oxytoca, 
MIC ≥ 8 µg/mL for cefpodoxime or MIC 
≥ 2µg/mL for ceftazidime, aztreonam,              ce
fotaxime, or ceftriaxone; and for P. mirabilis, MIC 
≥ 2µg/mL for cefpodoxime, ceftazidime, or 
cefotaxime). It is recommended that using more 
than one antimicrobial agent      in screening for 
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ESBL production improves the sensitivity of the 
detection method. 
Disk Diffusion Method 
Disk diffusion method detects reduced  suscepti
bility to two or more indicator antibiotics 
(Cefotaxime 30µg, Ceftriaxone 30µg,Ceftazidime
 30µg, Aztreonam 30µg, and Cefpodoxime10µg). 
Once an ESBL producer is suspected, it is then 
confirmed by standardized methods (EUCAST, 
2012).  
A suspension of the test isolates as well 
as the standard strains      is made using a loopful 
of its colony in normal saline to achieve a cell 
turbidity equivalent to the 0.5 McFarland 
turbidity 1.5×108CFU/mL. Then inoculums are      
aseptically streaked on     to the surface of Muller-
Hinton agar media using a wire loop. The 
antibiotic discs are aseptically placed on the 
surface of Muller Hinton agar using sterile 
forceps, leaving 15 mm away from the edge of 
the Petri dish, the disks were separated from 
each other by a distance not less than 20mm to 
avoid overlapping zones of inhibition. The 
inoculated media are then incubated at 37°C for 
16 hours. Zones of inhibition around the antibiotic 
disks are measured to the nearest mm and can 
be compared with the reference strains 
of E. coli (ATCC25922) and K. pneumonia          
(ATCC-700603) as negative and positive controls 
respectively (CLSI, 2015) 
ESBL Confirmation Methods 
E-test Strip (Epsilon test) 
The principle behind the ESBL E-test strip is 
dilution and diffusion. The ESBL E-test strip is a 
thin plastic, non-porous strip with dimensions 
60mm by 5mm, and bearing two shorter 
gradients aligned in opposite directions on the 
same strip (Nitin et. al., 2014), The strip is two 
sided containing a gradient of one of the 
Oxyiminocephalosporins (e.g. Ceftazidime alone) 
on one end and a gradient of Cephalosporin + 
Clavulanic acid (e.g. Ceftazidime plus 
clavulanate) on the other (Nitin et. al., 2014, 
Rahman et. al., 2014). The strip is inoculated on 
a surface of the agar plate and incubated 
overnight at 37°C. After incubation, any reduction 
of > 3 log 2 (doubling) dilution is considered as 
positive (Figure 1) (Vercauteren et al., 1997; 
Rahman, et. al., 2014). Numerous reports of 
ESBLs have been confirmed by the use of E-test 
from different parts of the world including      but 
not limited to      Kaur and Aggarwal, 2013; 
Rahman et. al., 2014; Singh and Lokhendro 
2014;Prabha et. al., 2016     . 
This method is sensitive, convenient and easy to 
use, but it is sometimes difficult to read the test 
when the minimum inhibition concentration 
(MIC)s of ceftazidime is low because the 
clavulanate sometimes diffuses over to the side 







Figure1: E-test showing enhance zone of inhibition towards cephalosporin plus clavulanic acid (Source: 
Vercauteren et. al.,1997).
Combination Disk Test (CDT)  
In this test, a disk containing cephalosporin alone 
(cefotaxime 30μg, or ceftazidime 30μg) is placed 
in opposite direction to a disk containing 
cephalosporin plus clavulanic acid (20/10μg) with 
a distance of 15 mm apart on Muller Hinton 
agar medium (Khosravi et. al.,2013;CLSI, 
2014;Anand et. al., 2016; Lohani et. al., 2019). 
The inoculated media are then incubated at 37oC 
for 18–24 hours. After incubation, zones of 
growth inhibition are measured to the nearest 
mm, a difference of >5 mm for a disk containing 
cephalosporin plus clavulanic acid compared to a 
disk containing cephalosporin alone is considered 
positive as shown in figure 2 (Naseer et. al., 
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2007; EUCAST, 2012; Anand et. al., 2016; 
Shiferaw et. al., 2019;). Shiferaw et. al., (2019) 
reported that combination disc test is better than 
double disc synergy test in detecting ESBLs. This 
method was found to detect ESBL producing 
Klebsiella with 100% sensitivity and specificity 
and was validated with both BSAC and NCCLS 
methods Carter et al., (2000) as reported by 
Livermore and Brown, (2001). Combination disc 
test is a simple and cost effective method of 
detecting ESBLs (Jabeen et al., 2003). Several 
studies (Livermore and Brown, 2001; Giriyapur 
et. al., 2011;EUCAST, 2012; SinghandLokhendro 
2014) recommended that      the combination disc 
test be used to confirm ESBL production. 
 
Figure 2: Zone of inhibition around disk with clavulanic acid and disk without clavulanic acid (Source: 
Mahmoud et. al., 2016).
ESBL Chrom Agar 
This test, offers a rapid screening method for the 
detection of ESBL producing Gram negative 
bacteria. The test organisms are inoculated on     
to a CHROMagar using spread plate technique of 
direct streaking, and then incubated at 37oC for 
18-24 hours. Colonies of ESBL producers develop 
species-specific colors as represented on Table 1 
and      Figure 3 (Hornsey et. al., 2013; Hassan 
and Abdalhamid 2014; Prabha et. al., 2016). The 
advantage of this method is that      it is rapid, 
sensitive and specific     ; it also inhibits the growth 
of other bacteria, including most of those carrying 
AmpC type resistance (Prabha et. al.,2016). 
Studies from Uyanga et al., 2019      and Prabha 
et. al., 2016       reported that ESBL CHROM agar 
test can be used to confirm      ESBL production. 
 
Figure 3: Species-specific colours developed by microorganisms on CHROM agar 
Labelled: 1 represent P. mirabilis; 2, E. faecalis; 3, K. pneumoniae; 4, P. aeruginosa; 5, E. coli; 6, S. 
aureus (Samra, et. al., 1998). 
 
Table 1: Differential colours of the various ESBL-     producing bacterial genera on Chrom agar. 
S/ No  Microorganism  Appearance of the colony 
1 Proteus mirabilis   
  
Brown halo 
2 Escherichia coli    Dark pink to reddish 
3 Klebsiella pneumonia Mucoid,xMetallic blue 
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4 Enterobacter aerogenes Metallic blue 
5 Citrobacter freundii Metallic bluey 
6 Acinetobacter sp    Cream, Nontransparent, 
7 Pseudomonas aeruginosa   Translucent, yellow serrated edges 
8 Stenotrophomonas    Colourless 
9 Morganellamorganii Clear diffusible beige on beige background 
10 Torulopsis glabrata Creamy, very small, indistinct 
11 Enterococcus faecalis. Dry, turquoise 
12 S. saprophyticus Pink, Opaque 
13 Staphylococcus aureus Opaque, white to yellowish 
14 Candidaalbicans Creamy, wet convex 
15 Pseudomonas aeruginosa. Transparent, yellow serrated edges, diffusez 
16 Streptococcus sp Small, translucent; diffuse light blue within agar 
17 Corynebacterium sp Colorless, small, undifferentiated 
18 Lactobacillus sp. Scanty, light blue within agar 
Legend; xSlight pink halo around the periphery after 24 to 36 hours. 
yStrong purple-pink halo (diffuse) after 24 to 36 hours. 
zGreen after 24 to 36 hours. 
(Source: Samra,  et al., 1998;Prabha et. al.,2016) 
Double Disk Synergy Test (DDST) 
 In this assay, an overnight broth culture of the 
test bacteria corresponding to 0.5 McFarland 
turbidity standard is aseptically streaked onto the 
surface of Mueller-Hinton medium (Rahman 
et. al., 2014). A susceptibility disk containing 
amoxicillin plus clavulanate (20/10μg) is 
aseptically placed in the center of the plate, and 
the cephalosporins disks (ceftriaxone, 
cefpodoxime, cefotaxime, or ceftazidime) are 
then placed around it at a distance of 15 mm from 
the center of the amoxicillin plus clavulanate disk 
(Farzana et. al., 2013; Yarima et. al., 2019). The 
inoculated media are then incubated overnight at 
37°C (Kaviyarasan, et. al.,2018). An increase in 
the zone of inhibition towards the centrally placed 
disk will be considered positive for ESBL 
production (Peter-Getzlaff., 2011; Caurasia et al., 
2015) as shown in Figure 4.This test is reliable for 
the detection of ESBLs provided that the 
sensitivity disks are placed at the recommended 
distance (Rahman et. al.,2014). Jabeen et. al., 
(2003) recommended that ESBL could be 
detected by the use of double-     disk synergy 
test, as the method is      cost effective and simple. 
Several other studies (Rahman et. al., 2014; 
Singh and Lokhendro 
2014; Chauhan et. al., 2015 Shu’aibu et.al.,      
2016; Falodun et. al., 2018: Yarima et. al.,2019) 
also buttressed the finding that DDST can be 
used to confirm ESBL production.
 
Figure 4: Zone of inhibition toward the centrally placed amoxicillin plus clavulanic acid disc between 
ceftazidime and cefpodoxime discs as exhibited by an ESBL producing bacterium (Source: Mangaiyarkarasi 
et. al., 2013)   
Three Dimensional Test 
In this method, two types of inocula are 
prepared, namely; three dimensional inoculum 
(109 to 1010 CFU/mL) and a standard disk 
diffusion test inoculum (0.5 McFarland turbidity 
standard) (Nitin et al., 2014). The surface of the 
Muller-Hinton Agar is inoculated by standard disk 
diffusion testing method, and a slit is made into 
the agar using a sterile scalpel blade, then a three 
dimensional inoculum is pipetted in     to the slit. 
Subsequently, antibiotic disks are placed on the 
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surface of the plate at a distance of 3 mm outside 
of the inoculated circular slit (Rawat and Nair, 
2010; Nitin et. al., 2014). While standard disk 
diffusion susceptibility test results are measured 
according to the recommendations of CLSI, the 
distortion or discontinuity in the expected circular 
inhibition zone is considered positive for ESBL 
production (Nitin et. al., 2014). Three 
dimensional test may be direct or indirect. 
Indirect modified three dimensional test, as 
reported by Shaikh et al., (2016) is better than 
double disc synergy test for ESBL detection. This 
test is very sensitive in detecting ESBL, but it is 
technically challenging and more labour intensive 
than other methods (Thomson and Sanders, 
1992). Reports from Rupp and Fey, (2003) and 
Rahman et.al., (2014) shows that this method is 
used in detecting ESBL production. 
Broth Micro     dilution test 
In this assay, a standard broth dilution procedure 
is employed using Ceftazidime 0.25–128 µg/mL, 
Ceftazidime plus clavulanate 0.25/4–128/4 
µg/mL and Cefotaxime 0.25–64 µg/mL, 
Cefotaxime plus clavulanate 0.25/4–64/4 µg/mL 
as recommended by CLSI. Following incubation 
at 37oC for 16 hours, phenotypic confirmation is 
considered as a ≥ 3 twofold serial dilution 
decrease in Minimum Inhibitory Concentration 
(MIC) of either cephalosporin in the presence of 
clavulanic acid compared to its MIC when tested 
alone. For confirmatory tests, both cefotaxime 
and ceftazidime alone and in combination with 
clavulanate can be used (CLSI, 2015). Swenso et. 
al., (2004),      Hoon et. al., (2009)     , EUCAST, 
(2012)     , CLSI, (2015) and Abdelmoktader and 
Talal, (2019) asserted that Broth Microdilution 
has been used to detect ESBL production.   
Vitek System 
This is an automated microbial identification and 
antibiotic susceptibility testing that can be used 
to confirm ESBLs in members of the family 
Enterobacteriaceae (Dashti et. al., 2006; Shah et. 
al., 2016). Several other studies (Rupp and 
Fey, 2003; Spnau et. al., 2006; Putra et. al.,     
2020) show      that Vitek 2 system can be used 
to detect ESBL Production. This assay relies on 
card wells containing 1.0 mg⁄L of cefepime, or 
0.5 mg⁄L of cefotaxime or ceftazidime, either 
alone or in combination      with 10 or 4 mg     ⁄L 
of clavulanate, respectively (Drieux et. al., 2008), 
following incubation, cards are introduced into 
the VITEK 2 machine, and for each antibiotic 
tested, turbidity is measured at regular intervals. 
An isolate is considered ESBL positive, if      a 
predetermined reduction in growth in wells 
containing clavulanic acid compared to those 
without clavulanic acid is observed (Drieux et. 
al.,2008; Rahman et. al., 2014). Computer 
algorithms in the vitek system have been used to 
categorize the beta lactamases present in Gram 
negative clinical isolates based on the phenotype 
of susceptibility patterns with various β-lactam 
antibiotics. This method is fast, sensitive and 
specific                (Rahman et. al., 2014)     ; the 
method      helps to identify Enterobacteriaceae 
up to genus and species levels (Dashti et. al., 
2006) and the susceptibility tests using      this 
method are expressed as MIC values and 
interpreted as susceptible, intermediate or 
resistant with      reference to a CLSI (Livermore 
and Brown, 2001; Dashti et. al., 2006; Shah et. 
al., 2016). 
Nordmann/Dortet/Poirel (NDP) test  
This test identifies ESBL producers based on      
biochemical detection of the hydrolysis of the β-
lactamring of cefotaxime. The procedure of 
Poirelet. al., (2016) as described by Afolabi et. al., 
(2017) is as follows. Briefly, 50µl of a 10% Triton 
solution is added into Eppendorf tubes labeled A, 
B, and C containing 0.5ml of blood culture      and 
the mixture is vortexed and incubated at room 
temperature for 5min followed by centrifugation 
at 13000g for 2min. The supernatant is discarded 
and the pellet is re-suspended in 500µl distilled 
water, the bacterial suspension is centrifuged 
again at 13,000 g for 2 min, the supernatant is 
discarded again and the bacterial pellet re     
suspended in 100µl of 20 mmol l-1Tris-HCl lysis 
buffer. Ten microliters (10µl) of 40 mgmL-1 
tazobactam solution is      added into tube C; and 
then 100µl phenol red (0.5%, w/v) into tube A 
and 100 µl phenol red supplemented with 
cefotaxime 6 mgmL-1 into tubes B and C. The 
tubes are incubated at 37o C for 15 min, change 
in colour from red to yellow/orange is  positive for 
ESBL production as shown in Figure 5 below 
(tube B) which contains cefotaxime alone while 
the tube containing cefotaxime supplemented 
with tazobactam remained red (unchanged). 












Figure 5: ESBL production exhibited by inoculum in tube B containing cefotaxime alone (Source: Affolabiet. 
al.,(2017)).
Conclusion 
Infections caused by ESBL-     producing bacteria 
often limits therapeutic options,      leading to high 
disease burden. Therefore, diagnostic 
laboratories are in need of reliable, cost efficient 
and less labour intensive methods to use in the 
detection of ESBL-     producing bacteria. Bacteria 
harbouring ESBL genes are capable of spreading 
these plasmids to other bacteria via horizontal 
gene transfer. The public health implications of 
this are disturbing thus the need to rapidly detect 
these pathogens in the laboratory. Several 
techniques of ESBL detection and confirmation 
have been comprehensively explored in this 
review and the choice of the testing method 
depends on the preferences and requirements of 
the laboratory professionals as well as the 
availability of the testing material. There is the 
need for reliable but simple phenotypic tests in 
the laboratory for      the detection of these ARB, 
which do not require highly skilled personnel, this 
is in order to ensure a swift response in the 
management and control of these pathogens. 
Policy makers in the relevant sectors need to 
implement strategies to ensure the rapid 
detection of ESBL-     producing bacteria in clinical 















Methods Merits/demerits   References  
1  
E-test  
Merits  sensitive and easy to use Rahman et. al., (2014); Nitinet. al., (2014); 
Prabha et al.,(2016) 
Demerits  Difficult to interpret, less sensitive compare to 
double-disk test 
 
Rahman et. al.,(2014) 
E-test is expensive  Prabha et. al., (2016); 
2  
Combination 
disk test  
Merits  
 
This method is better than DDST in the detection 
of ESBLs 




Merits  Rapid, sensitive and specific  
Prabha et. al., (2016) Demerits  CHROM agar test is expensive 





Merits  Reliable, Easy to use and interpret Rahman et. al., (2014) 
 
(Jabeen et. al.,(2003) Demerits Distance of disk placement not standardized 







simultaneous determination of antibiotic 
susceptibility and β-lactamase detection (but not 
specific for ESBLs)  
Singh and Kumar, (2013); Rupp and Fey, 
(2003); Nitin et al., (2014) 
Sensitive in ESBL detection  Thomson and sanders, (1992); Bradford, (2001) 




Merits  Results can be expressed quantitatively  
Alizade et al., (2016) 





automated microbial identification and antibiotic 
susceptibility testing 
Dashti et. al.,(2006); Shah et. al.,(2016) 
Fast, sensitive, specific  Rahman et. al.,(2014) 
Identifies Enterobacteriaceae up to genus and 
species level 
Dashti et. al.,(2006) 
Demerits  Reduced sensitivity Rahman et. al.,(2014) 
8  Merits  Simple, Rapid, cost‑effective, sensitive, specific 
and reliable  
Kumar et. al., (2018), Sadek and Nordmann, 
(2019) 






Demerits  The ability of  the enzyme to hydrolyze the 
substrate, the level of expression of the 
corresponding gene and the affinity of the enzyme 
for the substrate   
Sadek et. al., (2019) 
 Table 2: Brief summary of the merits and demerits of the methods used in detection of ESBL 
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